EXTEND: A 3-Year, Virology Follow up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies.
Phase of Trial: Phase IV
Latest Information Update: 08 Aug 2014
At a glance
- Drugs Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EXTEND
- Sponsors Vertex Pharmaceuticals
- 26 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
- 28 Sep 2011 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.